Literature DB >> 2509473

A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo.

Y Singh1, V K Chaudhary, S H Leppla.   

Abstract

Anthrax toxin is the only protein secreted by Bacillus anthracis that contributes to the virulence of this bacterium. An obligatory step in the action of anthrax toxin on eukaryotic cells is cleavage of the receptor-bound protective antigen (PA) protein (83 kilodaltons) to produce a 63-kilodalton, receptor-bound COOH-terminal fragment. A similar fragment can be obtained by limited treatment with trypsin. This proteolytic processing event exposes a site with high affinity for the other two anthrax toxin proteins, lethal factor and edema factor. Terminal sequencing of the purified fragment showed that the activating cleavage occurred in the sequence Arg164-Lys165-Lys166-Arg167. The gene encoding PA was mutagenized to delete residues 163-168, and the deleted PA was purified from a Bacillus subtilis host. The deleted PA was not cleaved by either trypsin or the cell-surface protease, and was non-toxic when administered with lethal factor. Purified, deleted PA protected rats when administered 90 min before injection of 20 minimum lethal doses of toxin. This mutant PA may be useful as a replacement for the PA that is the major active ingredient in the current human anthrax vaccine, because deleted PA is expected to have normal immunogenicity, but would not combine with trace amounts of LF and EF to cause toxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509473

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor.

Authors:  Vibha Chauhan; Rakesh Bhatnagar
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

2.  A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Authors:  G Hermanson; V Whitlow; S Parker; K Tonsky; D Rusalov; M Ferrari; P Lalor; M Komai; R Mere; M Bell; K Brenneman; A Mateczun; T Evans; D Kaslow; D Galloway; P Hobart
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

3.  Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

Authors:  T J Goletz; K R Klimpel; N Arora; S H Leppla; J M Keith; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

4.  Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells.

Authors:  Kuang-Hua Chen; Shihui Liu; Laurie A Bankston; Robert C Liddington; Stephen H Leppla
Journal:  J Biol Chem       Date:  2007-01-24       Impact factor: 5.157

5.  Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.

Authors:  Shihui Liu; Thomas H Bugge; Arthur E Frankel; Stephen H Leppla
Journal:  Methods Mol Biol       Date:  2009

Review 6.  Membrane translocation by anthrax toxin.

Authors:  R John Collier
Journal:  Mol Aspects Med       Date:  2009-06-27

7.  Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis.

Authors:  F Brossier; M Weber-Levy; M Mock; J C Sirard
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

8.  A Bacillus anthracis strain deleted for six proteases serves as an effective host for production of recombinant proteins.

Authors:  Andrei P Pomerantsev; Olga M Pomerantseva; Mahtab Moayeri; Rasem Fattah; Cynthia Tallant; Stephen H Leppla
Journal:  Protein Expr Purif       Date:  2011-08-07       Impact factor: 1.650

9.  Processing of proaugurin is required to suppress proliferation of tumor cell lines.

Authors:  Akihiko Ozawa; Adam N Lick; Iris Lindberg
Journal:  Mol Endocrinol       Date:  2011-03-24

10.  Toxin-induced resistance in Bacillus anthracis lethal toxin-treated macrophages.

Authors:  Isabelle I Salles; Amy E Tucker; Daniel E Voth; Jimmy D Ballard
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.